Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-53718678 in non-hospitalized adults with RSV infection
2017-003252-24Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rilematovir in respiratory syncytial virus disease (RSV) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Area under the RSV viral load-time curve. Started Nov 2017; status: completed.
02
Drugs
rilematovir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2017-003252-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003252-24.